Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout | Nasdaq
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Opinion: Three tech, three biotech companies that are top takeover targets in 2019 - MarketWatch
bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A (NASDAQ:BLUE) | Seeking Alpha
Bluebird Spinoff 2seventy Bio Gets Its Own Wings :: Scrip
5 Biotechs Drawing Buyout Buzz in 2018 | BioSpace
BLUEBIRDBIO
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
3 Top Biotech Buyout Candidates in 2021 | The Motley Fool
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
Bluebird Bio hits pause on rollout for ill-fated gene therapy Zynteglo as trial flags 2 cancer cases | Fierce Pharma
BLUEBIRDBIO
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first | Fierce Pharma
Will Bluebird Bio's Big Gamble Payoff? | Biotech Investing | Sick Economics
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets
Bluebird bio snares gene-editing tech in $156M buyout deal | Fierce Biotech
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
BLUEBIRDBIO
10 Takeover Targets of 2018
The top 10 takeover targets in biopharma | Fierce Biotech
Bluebird's Gene Therapy; Neurocrine-Sosei's Pact; Twist-Abveris's Deal
National Resilience forks over $110M for North Carolina manufacturing site in bluebird bio cell therapy partnership | Fierce Pharma
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
